• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Novartis unit Alcon posts modest Q2 gain

Novartis unit Alcon posts modest Q2 gain

July 18, 2017 By Brad Perriello

Novartis Alcon(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today.

The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss.

Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiterated today, including a possible initial public offering that he has suggested could value Alcon at $25 billion to $35 billion.

“It just increases the options we have,” Jimenez told reporters on a call. “It makes a capital markets exit a possibility, because you’ve got a growing business with presumably over time margins that are going to grow.”

The shares opened 1.1% higher in Zurich.

Novartis boosted Alcon’s full-year sales outlook slightly and now expects revenue to rise by a low single-digit percentage rate. It previously forecast revenue to remain stable or to rise by a low-single digit percentage.

“Although Alcon profits continued to decline, this is now moderating and showing signs that the company have it under control,” Deutsche Bank analyst Tim Race said.

For all of Novartis, second-quarter core net income fell 2% to $2.87 billion, but beat the average analyst forecast of $2.67 billion in a Reuters poll. Sales fell 2% to $12.24 billion, hurt by declining revenue from blood cancer drug Gleevec.

Jimenez underscored plans to return Novartis to growth in 2018, as newer drugs including heart failure medicine Entresto, psoriasis treatment Cosentyx and breast cancer medicine Kisqali make up for generic competition now eating into Gleevec sales.

Cosentyx sales rose 90% to $490 million, while Entresto more than doubled to $110 million and remained on track to hit $500 million this year.

Even so, U.S. pricing headwinds are working against Novartis’s Sandoz generics division, whose sales fell 5% to $2.5 billion. Fierce competition will continue, Jimenez said, predicting further mid-to-high-single-digit price erosion.

“Sandoz was soft,” Bernstein analyst Timothy Anderson said. “Volume growth was anaemic, and overwhelmed by steady price erosion.”

Analysts now hope Sandoz’s launch of biosimilars – knockoff versions of Roche’s blockbuster Rituxan and Amgen’s Enbrel won approval in June – will help but Jimenez tempered expectations. He remains uncertain how quickly these cheaper drugs will poach patients from name-brand rivals.

“We really don’t know yet what the market reaction will be,” he said. “This will be a slow burn, you shouldn’t see a big spike in it, but nice steady growth.”

Filed Under: MassDevice Earnings Roundup, Mergers & Acquisitions, Optical/Ophthalmic, Wall Street Beat Tagged With: Alcon, Novartis

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy